Gabapentin Dementia Lawsuit in Arkansas - Free Case Review

Free Case Review

Start Your Free Review

Answer 2-3 quick questions to review your potential case.

Key Takeaway

Arkansas ranks among the top ten states for per-capita gabapentin prescribing, driven by one of the nation's highest chronic pain rates and severe opioid crisis impact across the rural Delta and Ozark regions. The state's limited healthcare infrastructure — with many counties classified as medically underserved — means patients rely heavily on primary care providers who prescribe gabapentin broadly for pain conditions without specialist oversight. Arkansas has not scheduled gabapentin as a controlled substance, despite bordering states like Tennessee and Alabama that have taken this step. The state's large population of manual laborers in poultry processing, agriculture, and manufacturing face chronic occupational pain that drives long-duration gabapentin use at high doses.

Written By

People's Justice Legal Research Team

Statute of Limitations

Arkansas: 3 years for product liability (Ark. Code Ann. § 16-116-103). Discovery rule applies — limitations begin when plaintiff discovers or should have discovered the injury and its connection to the product.

3 years from discovery of injury

Filing Venue

Where to File in Arkansas

Arkansas gabapentin cases may be filed in the Eastern District (Little Rock) or Western District (Fort Smith, Fayetteville). Pulaski County Circuit Court in Little Rock handles complex litigation. Arkansas follows modified comparative fault with a 50% bar — plaintiff recovery is barred if plaintiff is 50% or more at fault. The state does not cap compensatory damages in product liability cases but has limitations on punitive damages.

Arkansas Data

Exposure in Arkansas

Source: IQVIA / AR PDMP data

Source: CDC prescribing rate data

Source: HRSA Medically Underserved Areas data

FAQ

Frequently Asked Questions

See details below.

Back to Gabapentin Dementia Lawsuit Lawsuit Overview